Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The University of Southampton have developed a unique DNA based therapeutic to activate NK cells against cancer. The therapeutic is delivered intramuscularly in combination with DNA encoding the potent immune stimulating cytokine IL-15.
The objective is for an Executive to jointly work with the team to bring the opportunity towards and ultimately achieve launch of a new spinout company.
The project description is included below:
Phase 1 Opportunity Validation and Business Plan Creation - Executive leads all activity; ensures other team members support on relevant technical/ application needs inputs; if requested by Exec, UoS R&IS department will assist defining business plan requirements
Phase 2 Research organisation Approval In Principle to Spinout - Executive briefed by UoS R&IS on relevant documentation, and assisted by that team to complete this and submit to first available regular bi-monthly Southampton Enterprise Board meetings; Attendance of networking conferences to accelerate commercialisation process.
Phase 3 Achieve "Ready to Spin" status
Phase 4 Investor willingness to complete necessary funding round;
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Lifescience Advisors Limited | 09358385 | £30,000 | - |